Arena Pharmaceuticals, Inc. (ARNA)

[sts66]

Appears you were right after all - I still claim this was a material event requiring an immediate 8-K though:

10k filing on 3/2/14.
http://biz.yahoo.com/e/140303/arna10-k.html

Under OVERVIEW AND RECENT DEVELOPMENTS

"We previously filed applications for marketing approval of BELVIQ with the regulatory authorities for the European Union and Switzerland, and these regulatory authorities notified us that we had not yet satisfactorily addressed their concerns and that our applications would not be approved. We expect to continue to work with Eisai in pursuing regulatory approvals for BELVIQ in Europe and other territories outside the United States."


Hey, wait a second! The Q4 CC was on 2/27, 10-K out on 3/2 - that's only two days between the two events! ARNA HAD to have known about the Swissmedic rejection prior to the CC but refused to issue an 8-K as required or disclose it during the CC - BS! And I'll bet if I were to take the time to listen to the CC I'd hear something like "negotiations are ongoing", whereas in reality it was already a done deal - another SEC violation!